STAAR Surgical (STAA) Misses Q2 EPS by 9c, provides guidance

STAAR Surgical (NASDAQ: STAA) reported Q2 EPS of $0.15, $0.09 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $99 million versus the consensus estimate of $95.22 million.

GUIDANCE:

STAAR Surgical sees FY2024 EPS of $340.00-$345.00, versus the consensus of $340.00, increased from prior outlook for net sales of $335 million to $340 million.
Adjusted EBITDA of approximately $42 million and Adjusted EBITDA per diluted share of approximately $0.80, increased from prior outlook of Adjusted EBITDA of approximately $39 million and Adjusted EBITDA per diluted share of approximately $0.75.

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
• Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
• Astera Labs, Inc. (ALAB) Tops Q3 EPS by 13c, Beats on Revenue